|
Orthologous residues
|
|
TSC2 (human): Y1571‑p, TSC2 iso3 (human): Y1527‑p, TSC2 iso4 (human): Y1548‑p, TSC2 (mouse): Y1572‑p, TSC2 iso6 (mouse): Y1550‑p, TSC2 (rat): Y1573‑p, TSC2 iso2 (rat): Y1530‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phospho-antibody, phosphoamino acid analysis, western blotting
|
|
Disease tissue studied:
kidney cancer
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast), COS (fibroblast), HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, monkey, mouse
|
|
Comments:
LEF8 (renal cancer cell line)
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
vanadate
|
|
|
|
increase
|
|
|
serum
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation, molecular association, regulation
|
|
Effect of modification (process):
cell growth, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
TSC1 (rat)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
